Payment overview · 2025
General Payments
$3,480.28
70 reported records · 15 companies
Healthcare provider profile · identity verified
Michael Tedla, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BRADENTON, FL · NPI 1689061657
Verified facts
What the public records show
CMS Open Payments records show Michael Tedla, MD received $3,480.28 in general payments during 2025 across 70 reported records.
Medtronic, Inc. accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,122.78 | 32.3% | 13 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $598.88 | 17.2% | 18 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $458.06 | 13.2% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $397.50 | 11.4% | 6 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $230.58 | 6.6% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $210.51 | 6.0% | 3 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $99.06 | 2.9% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $94.51 | 2.7% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $66.98 | 1.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.87 | 1.7% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $43.32 | 1.2% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $39.67 | 1.1% | 2 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $25.17 | 0.7% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $17.73 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.66 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,702.30 | 66 |
| Travel and Lodging | $777.98 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $1,016.41 | 6 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $224.68 | 12 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $224.68 | 12 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $223.56 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $220.18 | 5 | 2025 |
Source payment records
|
|||||
| INTHRILL THROMBECTOMY CATHETER Normalized: inthrill thrombectomy catheter |
Device | Stryker Corporation | $177.33 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $155.58 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Intracardiac Undivided Normalized: intracardiac undivided |
Device | Philips North America LLC | $147.05 | 2 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $133.89 | 2 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $123.24 | 2 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $107.34 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $94.51 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $82.18 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $63.46 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.87 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| Innova Vascular Normalized: innova vascular |
Device | Boston Scientific Corporation | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| HI-TORQUE COMMAND Normalized: hi torque command |
Device | Abbott Laboratories | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $13.36 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $8.29 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $5.56 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $4.70 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 226 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 81 |
| Eliquis | Apixaban | 135 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 116 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 35 |
| Losartan Potassium | Losartan Potassium | 76 | 22 |
| Furosemide | Furosemide | 75 | 35 |
| Lisinopril | Lisinopril | 57 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 56 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 18 |
| Potassium Chloride | Potassium Chloride | 47 | 20 |
| Spironolactone | Spironolactone | 39 | 13 |
| Xarelto | Rivaroxaban | 39 | 13 |
| Carvedilol | Carvedilol | 37 | 16 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,480.28 · 70 records | Medtronic, Inc. | ABRE, AMPLATZER AMULET, AMVIA EDGE, ARTIX MT, AZURE XT DR MRI SURESCAN, Acticor 7 VR-T DX, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CLOTTRIEVER BOLD CATHETER, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELUVIA, ENROUTE Transcarotid Neuroprotection System, ESPRIT, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE TAG Thoracic Branch Endoprosthesis, General - Therapies, HAWKONE, HI-TORQUE COMMAND, IN.PACT AV, INTHRILL THROMBECTOMY CATHETER, Indigo System, Innova Vascular, Intracardiac Undivided, LEQVIO, LUX-Dx Insertable Cardiac Monitor, Labosys, LifeVest, MYCARELINK, NAVITOR, OPTOWIRE, Penumbra System, REPATHA, SAVVYWIRE, TRICLIP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error